Insider Transactions in Q1 2023 at Karuna Therapeutics, Inc. (KRTX)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 09
2023
|
Stephen K. Brannan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-17.45%
|
$945,000
$189.51 P/Share
|
|
Mar 09
2023
|
Stephen K. Brannan Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+14.86%
|
$25,000
$5.45 P/Share
|
|
Feb 21
2023
|
Troy A. Ignelzi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,000
-16.44%
|
$1,140,000
$190.01 P/Share
|
|
Feb 21
2023
|
Troy A. Ignelzi Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+14.12%
|
$54,000
$9.2 P/Share
|
|
Feb 09
2023
|
Stephen K. Brannan Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,650
+26.78%
|
-
|
|
Feb 09
2023
|
Stephen K. Brannan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-25.0%
|
$960,000
$192.37 P/Share
|
|
Feb 09
2023
|
Stephen K. Brannan Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+20.0%
|
$25,000
$5.45 P/Share
|
|
Feb 09
2023
|
Troy A. Ignelzi Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,650
+22.1%
|
-
|
|
Feb 09
2023
|
Andrew Craig Miller President of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
12,550
+28.88%
|
-
|
|
Feb 09
2023
|
Steven M Paul |
BUY
Grant, award, or other acquisition
|
Direct |
11,400
+50.0%
|
-
|
|
Feb 06
2023
|
William P Kane Jr Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,656
+50.0%
|
-
|
|
Jan 18
2023
|
Troy A. Ignelzi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
200
-0.91%
|
$40,000
$200.14 P/Share
|
|
Jan 18
2023
|
Troy A. Ignelzi Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
200
+0.9%
|
$1,800
$9.2 P/Share
|
|
Jan 17
2023
|
Troy A. Ignelzi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
817
-3.61%
|
$164,217
$201.41 P/Share
|
|
Jan 17
2023
|
Troy A. Ignelzi Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
817
+3.48%
|
$7,353
$9.2 P/Share
|
|
Jan 13
2023
|
James Healy |
SELL
Open market or private sale
|
Indirect |
6,027
-100.0%
|
$1,199,373
$199.9 P/Share
|
|
Jan 12
2023
|
James Healy |
BUY
Other acquisition or disposition
|
Indirect |
6,027
+50.0%
|
-
|
|
Jan 12
2023
|
James Healy |
SELL
Other acquisition or disposition
|
Indirect |
300,000
-14.48%
|
-
|
|
Jan 09
2023
|
Stephen K. Brannan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-14.02%
|
$985,000
$197.52 P/Share
|
|
Jan 09
2023
|
Stephen K. Brannan Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+12.14%
|
$30,000
$6.36 P/Share
|
|
Jan 03
2023
|
Laurie J Olson |
SELL
Open market or private sale
|
Direct |
1,000
-100.0%
|
$197,000
$197.48 P/Share
|
|
Jan 03
2023
|
Laurie J Olson |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+50.0%
|
$84,000
$84.86 P/Share
|
|
Jan 03
2023
|
William Meury President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
38,073
+50.0%
|
-
|